Protean Presents Data on Breast Cancer Disparities in African American Women at SABCS
New Data on the Molecular Basis of Breast Cancer in African American Women
Although progress is being made against breast cancer in general, it seems African American women are being left behind.
Genevra Magliocco, a summer intern from Protean BioDiagnostics presents her study entitled “Distinct and targetable molecular features of breast cancer in African American women” which was aimed at determining if breast cancer occurring in African American women might have different molecular features.
The study evaluated data from the Cancer Genome atlas project and data from recent clinical trials. Bioinformatic analysis revealed that cancers occurring in African American women have a distinct molecular profile than those occurring in Caucasian women. In addition, data from recent clinical trials uncovered that African American women are severely under-represented in clinical trial enrollment.
Although African American women have a lower incidence of breast cancer, their outcomes when they develop the disease are significantly worse. The findings from Protean BioDiagnostics provides some insight as to the reason for this.
It appears that further work will be needed to close the disparities affecting breast cancer outcomes in African American women. Their tumors may have a different molecular basis, which opens opportunities for development of new diagnostics and treatment strategies. In addition, further efforts are required to increase representation of African American women in clinical trials.
Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from SABCS® and the author of this poster.
Contact Genevra Magliocco at gmaglioc@bu.edu for more information.
Protean BioDiagnostics is an innovative cancer diagnostics company and home of the revolutionary Oncology MAPS System designed to accelerate access to precision cancer treatments for under-serviced patients. The Oncology MAPS system uncovers new treatment opportunities for patients and enables improved patient matching to clinical trials.